		Application No.	Applicant(s)
Office Action Summary		10/528,892	HOSHINO ET AL.
		Examiner	Art Unit
	·	Christian L. Fronda	1652
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply			
A SH WHIC - Exter after - If NC - Failu Any r	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DATE in a sign of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. In period for reply is specified above, the maximum statutory period vere to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATIO 36(a). In no event, however, may a reply be ti will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONI	N. mely filed n the mailing date of this communication. ED (35 U.S.C. § 133).
Status			
2a)⊠	Responsive to communication(s) filed on 19 March 2007. This action is FINAL. 2b) This action is non-final. Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.		
Dispositi	on of Claims		
 4) ☐ Claim(s) 1.3 and 5-8 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) 5 and 7 is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or election requirement. 			
Applicati	on Papers		
 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on 25 March 2005 is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. 			
Priority u	ınder 35 U.S.C. § 119		
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 			
2) Notic 3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal I 6) Other:	Date

Art Unit: 1652

DETAILED ACTION

- 1. Claims 1, 3, 5-8 are pending and under consideration in this Office Action.
- 2. The rejection of claims 1, 3, 5-7 under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement has been withdrawn in view of applicants' amendment to the claims filed 03/19/2007.

Claim Rejections - 35 U.S.C. § 112, 1st Paragraph

- 3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

 The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- 4. Claims 1, 3, 6, 8 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. New grounds of rejection are stated in view of applicants' amendment to the claims filed 03/19/2007.

Factors to be considered in determining whether undue experimentation is required, are summarized In re Wands [858 F.2d 731, 8 USPQ 2nd 1400 (Fed. Cir. 1988)]. The Wands factors are: (a) the quantity of experimentation necessary, (b) the amount of direction or guidance presented, (c) the presence or absence of working example, (d) the nature of the invention, (e) the state of the prior art, (f) the relative skill of those in the art, (g) the predictability or unpredictability of the art, and (h) the breadth of the claim.

Regarding amended claims 1, 3, 6, 8 it is apparent that Sinorhizobium meliloti IFO 14782/pVK601, Sinorhizobium meliloti PY-C341K1, and Sinorhizobium meliloti PY-EGC1 are required to practice the claimed invention. The specification discloses on page 12, Table 1, that the amount of pyridoxal (mg/L) produced for each is 119, 171, 362, respectively, that Sinorhizobium meliloti PY-C341K1 has acquired a phenotypic property of histidine requirement, and that Sinorhizobium meliloti PY-EGC1 has acquired a phenotypic property of glycine resistance. Applicants' deposit of Sinorhizobium meliloti PY-EGC1 and statement that all restrictions on its the public availability will be irrevocably removed upon the granting of a patent in the amendment filed 03/19/2007 is acknowledged.

Art Unit: 1652

However, the processes used to make Sinorhizobium meliloti IFO 14782/pVK601 and Sinorhizobium meliloti PY-C341K1 using plasmids pVK100, pRK290, pLAFRI, and/or RSF1010 do not appear to be repeatable. The nucleotide sequences of the plasmid vectors used are not fully disclosed, nor have all the nucleotide sequences required for their construction been shown to be biblically known and freely available. The specification teaches searching and screening for specific microorganisms that have the desired properties of pyridoxal overproduction and phenotypic properties of histidine requirement and glycine resistance which does not appear to be repeatable.

Page 3

An enabling deposit of *Sinorhizobium meliloti* IFO 14782/pVK601 and *Sinorhizobium meliloti* PY-C341K1 and plasmids pVK100, pRK290, and pLAFRI may overcome the rejection. If the deposit is made under the terms of the Budapest Treaty, then an affidavit or declaration by the applicant, or a statement by an attorney of record over his/her signature and registration number, stating that the specific microorganism has been deposited under the Budapest Treaty and that the strain will be irrevocably and without restriction or condition released to the public upon the issuance of the patent, would satisfy the deposit requirement made herein.

If the deposit has not been made under the Budapest Treaty, then in order to certify that the deposit meets the criteria set forth in 37 C.F.R. 1.801-1.809 and MPEP 2402-2411.05, the applicant may provide assurance or compliance by an affidavit or declaration, or by a statement by an attorney of record over his/her signature and registration number, showing that:

- (1) during the pendency of this application, access to the invention will be afforded to the Commissioner upon request;
- (2) all restriction upon availability to the public will be irrevocably removed upon granting of the patent;
- (3) the deposit will be maintained in a public repository for a period of 30 years or 5 years after the last request or for the effective life of the patent, whichever is longer; and
- (4) the deposit will be replaced if it should ever become inviable.

Conclusion

- 5. No claim is allowed.
- 6 Claims 5 and 7 objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
- 7. Applicants' amendment necessitated the new ground(s) of rejection presented in this

Art Unit: 1652

Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

- 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christian L. Fronda whose telephone number is (571)272-0929. The examiner can normally be reached Monday- Friday from 9:00AM 5:00PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura N. Achutamurthy can be reached on (571)272-0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
- 9. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

CLF